The most advanced oncolytic Newcastle disease virus (NDV) strains that are used in clinical trials for the treatment of cancer are wild-type mesogenic strains. These virus strains have an inherent, nongenetically engineered, oncolytic activity and selectively replicate in tumor cells but not in normal human cells. To date no investigations have been performed with genetically engineered mesogenic NDV regarding the oncolytic activity. We describe here the generation of recombinant viruses of the mesogenic naturally oncolytic NDV strain MTH68. We show that not only one, but also two additional transgenes coding for amino-acid chains with a molecular weight of 25 and 50 kDa can be inserted into the viral genome without affecting viral growth, oncolytic potency or tumor-selective replication of the virus. Transgenic expression of the heavy and light chains of a monoclonal antibody, as separate additional transcriptional cassettes, leads to the expression of full immunoglobulin G (IgG) monoclonal antibody by recombinant NDV. Infection of tumor cells with antibody-transgenic viruses results in the efficient production and secretion of a functional full size IgG antibody by the tumor cells, that specifically binds to its target-antigen in tumor tissue. This approach will allow to combine the advantages of oncolytic RNA viruses and monoclonal antibodies in a single powerful anticancer agent with improved or even new therapeutic properties.
Introduction
The Newcastle disease virus (NDV) has long been known as a natural oncolytic virus 1, 2 that can replicate in human tumor cells but not in normal human cells, and therefore has attracted researchers to develop it as an antitumor agent. [3] [4] [5] [6] [7] According to its pathogenicity in chicken, NDV is classified into lentogenic, mesogenic and velogenic strains. 8 The viruses that have been shown to selectively replicate in tumor cells and have antitumor activity in xenograft tumor model experiments belong to the mesogenic class (that is, pathogenic for chicken). To date two NDV strains have been used in patient tumor treatment, MTH68 with published case reports [9] [10] [11] [12] and PV701 in clinical trials, the latter showing signs of efficacy. [13] [14] [15] A reverse genetic system to engineer the NDV genome was first described for the lentogenic (vaccine) strains LaSota by Peeters et al. 16 and Clone 30 by Rö merOberdö rfer et al., 17 and later the strain Hitchner B1. 18 Since then, the expression of various transgenes by these lentogenic NDV strains has been described. 19, 20 Recently an NDV (strain LaSota) with a transgene encoding for granulocyte macrophage colony-stimulating factor (GM-CSF) as a vector for cancer immunogene therapy was described. 21 Although virulent strains of NDV were analogously generated as recombinant viruses like Beaudette C 22 and Herts 33, 23 no recombinant virus of strains that had been tested in patients and been shown to be safe in humans has yet been developed. For the mesogenic NDV strain Beaudette C, it was shown by Krishnamurthy et al. 22 that insertion of a transgene results in growth retardation and attenuation of the virus. Therefore it was not clear whether every strain would be amenable by reverse genetics, like the lentogenic vaccine strains, without significantly affecting its replication. Since in the Beaudette C study the CAT transgene was inserted between the HN and L genes of the genome and because it is known that the viral transcription declines gradually toward the 5 0 end of the genome, 24 it was likely that a more 3 0 position of the transgene may result in decreased attenuation of a recombinant virus.
Here we describe the generation of a recombinant NDV strain MTH68 with one or two transgenes inserted between the F and HN genes without adversely affecting its replication potency.
From experience with various oncolytic viruses, it is clear that treatment with the naturally oncolytic virus alone may be insufficient for an effective antitumor response, prompting combination treatment. 25 Therefore strategies were developed to use either the virus in combination with other treatments or to 'arm' the virus with transgenes possessing a therapeutic activity when expressed by the infected tumor cells. Examples from the class of oncolytic RNA viruses include measles virus harboring the transgene for the sodium-iodide symporter NIS 26, 27 or GM-CSF 28 and vesicular stomatitis virus harboring the transgene for cytokines or thymidine kinase. 29, 30 In order to improve the tumor-targeting of oncolytic NDV, it has been suggested to exploit bispecific adapter proteins. 31 Recombinant NDVs with additional transgenes to improve their oncolytic potency were described very recently by Vigil et al. 32 In that report an originally lentogenic strain of NDV with an engineered furin cleavage site of the F protein was used as a viral backbone. Here we describe the engineering of a mesogenic NDV strain that has oncolytic activity as a wild-type strain.
Antibodies are widely accepted as effective antitumor agents. They are easily available with high specificity and affinity against almost any antigen, which is relevant for tumor growth or tumor maintenance. Therefore it was appealing to try the expression of a full monoclonal antibody by an oncolytic virus. The oncolytic virusmediated delivery of therapeutic antibodies is especially of interest because (1) viral-mediated delivery may lead to high local concentrations of the antibody in the tumor, (2) if desired even intracellular expression and targeting of intracellular targets is feasible and (3) the combination of therapeutic efficacy of antibody and the oncolytic effect of the virus may lead to synergistic effects.
To establish full monoclonal antibody expression by an oncolytic virus two transgenes (heavy and light chain) had to be simultaneously expressed in an equimolar ratio allowing formation of functional antibody. It was also necessary to demonstrate antibody-producing functionality in tumor cells that are otherwise incapable of immunoglobulin G (IgG) production. A monoclonal antibody, directed against the extradomain B (ED-B) of fibronectin, a tumor-specific vascular marker antigen 33 was chosen as a model.
In this study we describe the generation of recombinant oncolytic NDV strain MTH68 and the viral expression of full IgG antibodies by tumor cells that were infected with recombinant oncolytic NDV harboring the genes for the antibody heavy and light chains.
Results

Generation of a recombinant oncolytic NDV
A recombinant virus of the strain MTH68 was generated analogous to the method described by Schnell et al. 34 and Rö mer-Oberdörfer et al. 17 Primers were designed based on the sequence of the NDV strain LaSota and own sequence data. In a multistep cloning procedure a fulllength genomic plasmid was generated containing the 15186 nucleotide genome of NDV MTH68 (Figure 1a ). PCR fragments derived by high-fidelity PCR were sequentially cloned into the plasmid pX8dT 34 to obtain the plasmid pflMTH68. Additionally the open reading frames (ORFs) for the genes of N, P and L were cloned into the T7-expression plasmid pCITE to obtain helper plasmids for virus rescue. In order to rescue recombinant virus, BHK cells stably expressing the T7 polymerase were co-transfected with the pflMTH68 and the helper plasmids pCITE N MTH68, pCITE P MTH68 and pCITE L MTH68. After 1-2 days plaques formed that contained newly generated recombinant viruses. Reverse transcription (RT)-PCR of virus RNA followed by sequencing analysis confirmed the identity of the recombinant virus, which included an additional engineered XbaI site introduced during cloning and absent from the parental virus (not shown).
Thus the successful generation of a recombinant virus of the NDV strain MTH68 was achieved.
In order to express foreign transgenes using a recombinant virus, two additional transcriptional cassettes were cloned into the full-length genomic plasmid of pflMTH68 between the genes encoding the F protein and the HN protein into the unique SfiI restriction site (Figure 1b ). For the insertion of a single transgene a unique PacI restriction site followed by a gene stop and gene start signal for the viral transcription were inserted yielding pflMTH68 Pac (Figure 1b ). For the insertion of two additional transgenes, a unique AscI restriction site followed by a gene stop and gene start signal for the viral transcription were inserted yielding pflMTH68 Asc Pac (Figure 1b) . The gene start and gene stop sequences were copied from the transcriptional cassette for the N gene. The synthetic oligonucleotides were designed so that after insertion of the desired transgenes the genome length still followed the rule of six. 24, 35 The gene for the enhanced green fluorescent protein (EGFP) was amplified by PCR with primers containing PacI recognition sites, and the resulting PCR product was then inserted into the unique PacI site of pflMTH68 Pac (Figure 1b) . Recombinant virus was generated and named MTH87. Plaques that formed in the BHK-T7 cells after transfection showed green fluorescence when analyzed by microscopy confirming the expression of the transgene (not shown).
To generate a virus for the expression of a full IgG antibody, both the light and the heavy chain of the murine IgG antibody MOR03257 had to be cloned into the genomic plasmid. The light chain was PCR-amplified from a eukaryotic expression plasmid with primers containing AscI recognition sequences and cloned into the AscI site of pflMTH68 Asc Pac. The heavy chain was analogously PCR amplified from a eukaryotic expression plasmid with primers containing PacI recognition sequences and cloned into the Pac site of pflMTH68 Asc Pac. Recombinant virus was rescued and the resulting virus was named MTH146.
As an expression control, a virus coding for the gene for Escherichia coli b-glucuronidase was generated. The gene was amplified by PCR with Escherichia coli genomic DNA as a template with primers specific for the E. coli gene uidA. The ORF was cloned into pflMTH68 Pac and recombinant virus was rescued; this virus was named MTH115.
GFP expression allows monitoring of the oncolytic effect
The newly generated virus MTH87 containing the transgene EGFP could be used to monitor viral infection (Figure 2 ). This experiment illustrates the spread and the oncolytic effect of the NDV strain MTH68 directly in a living tumor cell line, which had not been possible before with the unmodified wild-type strain.
Transgene expression does not affect the viral growth
To investigate whether additional genes in the virus genome had a negative effect on the growth kinetics of the virus, virus titer growth curves were measured in MTH68-sensitive HT29 colon cancer cells (Figure 3a) . 
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Recombinant oncolytic NDV retain oncolytic potency and tumor-selective cytotoxicity
As a next step it had to be tested whether the transgeneexpressing recombinant viruses maintain the same oncolytic potency as the parental virus. For this purpose, decreasing virus MOIs (multiplicity of infections) were used to infect a confluent monolayer of HT29 human colon cancer cells (20 000 cells per 96 well). Two days post infection, the cell viability was measured ( Figure 3b ). Both the wild-type virus MTH68 and the recombinant viruses MTH115 and MTH146 exhibited very potent oncolytic activity even at low MOIs. Transgene-expressing recombinant viruses induced the same cytotoxicity level as their parental controls.
When the same experiment was performed in the nontumor cell line Hs68 in comparison with the tumor cell line HT29, an B1000-fold therapeutic window was observed, which is unaffected by the transgene expression of the recombinant viruses ( Figure 3b ).
Altogether we conclude that foreign transgene expression by oncolytic MTH68 does not hinder its oncolytic potency or tumor selectivity.
Recombinant NDV selectively replicates in tumor cells
With the EGFP-expressing virus MTH87, a tool was available to directly visualize infected cells by fluorescent microscopy on a single-cell basis; this allowed to investigate the tumor-selective replication of the mesogenic and naturally oncolytic NDV strain MTH68 in nontransformed versus transformed cells.
HT29 human colon cancer cells and nontransformed human keratinocytes HaCaT were mixed at ratios of 9:1, 1:1 and 1:9 and co-cultured as confluent monolayers. In order to identify the individual cells, the HaCaT cells were unspecifically labeled with the CellTrackerOrange prior to mixing with HT29 cells. The mixed cultures were then infected with an MOI of 0.001 of the EGFP-encoding virus MTH87. Early after infection (16 h; Figure 4 This experiment demonstrates that in a single dish, the infection with the recombinant virus at low MOI results in a selective transgene expression in the tumor and not in the nontransformed cells.
Expression of an anti-ED-B IgG by co-transfection in CHO cells
Before cloning of the genes for the heavy and light chains of the anti-ED-B antibody MOR03257 into the virus genome, the functionality of the genes and antibody expression was established by co-expression in cells. Therefore, eukaryotic expression plasmids with the individual genes for the heavy chain and the light chain of the anti-ED-B antibody MOR03257 were co-transfected in Chinese hamster ovary (CHO) cells.
Two days after transfection, the supernatant of the cells was harvested and assayed with ED-B antigen-coated enzyme-linked immunosorbent assay (ELISA) plates. Expression of the individual antibody chains alone did not produce a signal in the ELISA (Figure 5a ). Co-transfection of expression plasmids for both the heavy and the light chains of the antibody resulted in the expression of a functional antibody that could bind to its antigen ED-B. The observed IgG antibody concentration in the cell supernatant was 3.7 mg ml À1 as was calculated from an ELISA using purified antibody as reference molecule. Based on this experiment, the two antibody genes from the eukaryotic expression plasmids were cloned into the genomic plasmid of the virus.
Cells infected with MTH146 produce an antibody that binds its antigen ED-B fibronectin
To test whether the recombinant virus MTH146 containing the two foreign transgenes encoding anti-ED-B IgG would express antibody after infection, CHO cells were infected with a low MOI of MTH146. CHO cells are a standard production cell line for antibody production and have been shown to be very sensitive to infection by NDV strain MTH68 (not shown). As a control, cells were infected with the same MOI of a virus expressing an irrelevant transgene that results in expression of the secreted product b-glucuronidase (MTH115). After infection with MOI of 0.01, an aliquot of the supernatant was taken at the indicated time points. The supernatants were subsequently analyzed for functional antibody expression in an anti-ED-B ELISA, and it was found that the MTH146-infected cells released increasing amounts of ED-B-specific antibody into the supernatant over the course of the infection (Figure 5b) . No antibody could be detected in the supernatant after infection with the control virus. Maximum concentrations of the antibody were reached after 6 days and were in the range of 20-25 mg IgG per ml. This demonstrates that MTH146-infected cells express and secrete functional antibody against ED-B.
Viral expression of the transgenic antibody is tumor cell specific
To demonstrate virus-mediated antibody expression in other cells than CHO cells, we infected human tumor and normal cells with MTH146. Analyzed tumor cells included the human colon cancer cell lines HCT116 and HT29 and the human non-small cell lung cancer cell line NCI H460; normal cells included primary fibroblasts, the fibroblast cell line Hs68 and the nontransformed keratinocyte cell line HaCaT. Confluent monolayers of cells were infected with MTH146 at an MOI of 0.01. Antibody concentrations in the cell supernatant were determined after 2 and 5 days post infection. No signal was detected in the supernatants of the normal cells indicating that these cells do not produce measurable amounts of antibody (Figure 5c ). The supernatants of the infected tumor cells contained antibody in concentrations between 8 and 18 mg IgG per ml, with the highest concentration detectable in the HCT116 supernatant.
The degree of cell damage due to viral infection was similar in all the virus-sensitive tumor cell lines. No cell We conclude that infection with MTH146 leads to a selective expression of antibody in tumor cells but not in normal cells.
Antibody expressed from virus-infected cells binds to tumor cell-derived EDB antigen
The ELISA data showed that antibody expressed from virus-infected cells binds to the recombinant immobilized antigen ED-B. As a next step it had to be A natural source of the ED-B antigen are the murine F9 teratocarcinoma cells. 36 These cells are sensitive to NDV. Therefore we infected F9 cells with MTH146 at a low MOI of 0.01 and assayed antibody expression and binding 2 days after the infection by immunofluorescence experiments ( Figure 6 ). As a control, mock-infected cells were incubated prior to fixation with 5 mg ml À1 purified antibody for 1 h. After fixation, bound antibody was visualized with a secondary antibody directed against mouse IgG.
Mock-and control virus (MTH115)-infected cells did not produce an immunofluorescent signal, whereas a specific immunofluorescent extracellular staining was found with the purified antibody and the antibody from the virus-mediated expression. Thus the virally produced antibody concentration in the cell supernatant is sufficient to produce a staining similar to a purified antibody with a concentration of 5 mg ml
À1
. That is consistent with the estimated concentration of the virally expressed antibody, which was in the range of 5 mg ml À1 and is reported above. This result demonstrates that the antibody, expressed and secreted from MTH146 virusinfected cells, binds specifically to its native antigen as it is expressed from tumor cells. 
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The virally expressed antibody binds specifically to its target in tumor tissue
To further confirm the functionality of the virally expressed antibody it was tested whether the antibody that was expressed by virus-infected tumor cells could bind to its target as it is deposited in tumor tissues. Therefore tumor tissue sections were stained in immunohistochemistry experiments either with the purified anti- (Figure 7a ). From this result we conclude that the antibody from virus mediated expression is able to specifically bind its target ED-B as it is present in tumor tissue sections and that the concentration in the supernatant of infected cells is sufficient to produce a signal comparable to 5 mg ml À1 recombinant purified antibody. Because 293 cells are not tumor cells, we also tested virus originating from MTH146-infected tumor cells. Crude supernatant from three different tumor cells that had been infected with MTH146 produced a strong signal in the immunohistochemical staining that was specific for ED-B (Figure 7b ) and indistinguishable from stainings with the purified antibody (not shown). Incubation of tumor sections from the same tumor with cell supernatants from three nontumor cell lines, which had been infected in parallel to the tumor cells with MTH146, did not result in a positive immunohistochemical staining (Figure 7b ).
Since the viral expression of the antibody may be different in a tumor in vivo compared to tissue culture monolayer cell, we finally investigated virus-infected tumors in vivo. Nude mice with HT1080 tumor xenografts were infected intratumorally with either virus encoding for the antibody or with virus encoding for an unrelevant transgene. Three days after the infection, mice were killed and frozen sections of the tumors were prepared. Serial frozen sections were subsequently analyzed by immunohistochemistry. As a control the sections were stained with the purified antibody against ED-B to visualize the expression of the antigen ED-B in the HT1080 tumor model. In order to detect antibody within the tumor that originated from viral infection of the tumor cells, the sections were stained with protein A as a marker for IgG as before. Figure 8 demonstrates that only tumors that were infected with the virus encoding for the antibody show a positive staining with protein A as a marker for in vivo antibody expression (d). Tumors infected with a control virus do not give a signal (b). It is noteworthy that the antibody that is secreted by the tumor cells in vivo (Figure 8d ) is expected to have a different staining pattern than the purified antibody that is applied onto the sections in vitro (Figures 8a and c) . Whereas the purified antibody is added to the surface of the tumor section in vitro, the virally expressed antibody binds to the target in vivo within the intact tissue.
We conclude that antibody expressed and secreted from virus-infected tumor cells is fully functional and binds specifically to its target antigen as it is present in tumor tissues. Furthermore the results demonstrate that only infected tumor cells but not normal cells produce functional antibody after infection with the recombinant virus MTH146.
Discussion
We have generated a recombinant Newcastle disease virus based on the natural oncolytic mesogenic strain MTH68. The insertion of EGFP as an additional transgene allows monitoring of the virus replication in living cells. Therefore it was possible to follow the course of the oncolysis in vitro in real time. The cell line used in that experiment (HT29) does not show extensive syncytia formation upon infection with MTH68. Therefore the cytopathic effect is very slow compared to other cell lines that show massive cell-cell fusion after infection (not shown). Cell lines with strong syncytia formation (for example, HeLa) are killed more rapidly in the range of 12-24 h. The experiment was performed using confluent HT29 cells. Therefore we assume that the spread of the virus in the confluent monolayer of cells and the observed oncolysis are not dependent on cell proliferation and also effective in nondividing cells.
We could demonstrate that the oncolytic NDV strain MTH68 tolerates the insertion of one or two additional transgenes without any loss in virus potency and virus replication. The limit for the 'payload' of oncolytic NDV is therefore not reached yet and it remains to be determined how many foreign transgenes may be expressed and which maximal genome size may be tolerated by oncolytic paramyxoviruses. Skiadopoulos et al. 37 have published for human parainfluenza virus (HPIV) that up to three foreign genes can be incorporated into a paramyxovirus. However they observed an attenuation of the parental virus and a significant loss of titer. Since in that study glycoproteins were used as transgenes that may be incorporated into the virus particle, the same degree of attenuation may not be seen when different foreign transgenes will be used instead. In the present study we see no viral growth reduction, no attenuation of the oncolytic effect and no effect on the tumor selectivity of transgenic NDV after incorporating up to two additional transgenes and 2.3 kb additional genetic sequence into the virus genome. It is therefore very likely that multiple therapeutic transgenes can be incorporated without negatively affecting the Antibody expression by oncolytic NDV F Pühler et al oncolytic properties. Likewise the insertion of multiple reporter genes for imaging (for example, GFP for in vitro, luciferase or NIS for in vivo) simultaneously or in combination with therapeutic transgenes is conceivable.
We show that the transgene GFP is selectively expressed in tumor cells in a co-culture experiment with nontransformed cells. The tumor-selective replication of naturally oncolytic viruses has been shown by several groups. 5, 6, [38] [39] [40] It has been proposed for NDV that defects in the interferon pathway are a characteristic of tumor cells rendering these tumor cells vulnerable to virus replication. 41 Consistent with that hypothesis we see an initial infection with MTH87 and viral transgene expression in both nontransformed (HaCaT) cells and transformed (HT29) cells. Whereas the HaCaT cells will produce interferon and therefore become resistant to further virus replication, the HT29 cells do not respond with an interferon response and allow further virus replication. In the case of HT29 cells the tumor cells can also even not be protected by the paracrine action of interferon released by the infected neighboring HaCaT cells.
To demonstrate expression of a potent therapeutic molecule from virus-infected tumor cells we used as a model antibody a monoclonal antibody directed against the extradomain III type B fragment of fibronectin (ED-B) which is specifically upregulated in the extracellular matrix of growing tumors and is a marker of tumor angiogenesis. 42 The antibody has a function-blocking activity and blocks the adhesion of human umbilical vein endothelial cells (HUVECs) to ED-B. 43 In in vitro experiments this antibody blocks cellular adhesion with an IC 50 below 5 mg ml À1 (5 nM) and a delay of F9 teratocarcinoma tumor growth in vivo has been achieved with this antibody in the Fab format. 43 Currently this antibody is under preclinical evaluation for its antiangiogenic and antitumorigenic activity.
After infection of cells with the oncolytic virus MTH146 (harboring the transgene for the ED-B antibody) antibody concentrations in the cell supernatant were in the range of 20 mg ml À1 of functional antibody as determined in ELISA-binding experiments. This concentration can be sufficient for therapeutic efficacy in vitro as the IC 50 value for the antibody to block HUVEC adhesion to EDB-coated plates is in the low nM concentration range. 43 How this translates into necessary therapeutic active concentrations in vivo is difficult to predict. In contrast to current antibody therapies, where the antibody is repeatedly administered systemically, virally mediated expression is predicted to result in a high local expression at the site of the virus replication that is, tumor tissue. Within the tumor tissue the actual amount of antibody is therefore expected to exceed by far the concentration that may be measured systemically due to release into the blood system and which may indicate target saturation. Also it should be noted that viralmediated delivery could ensure a more homogeneous delivery of therapeutic molecules into the tissue of a solid tumor as the antibody is expressed by many infected tumor cells. That fact can provide a real improvement because systemically delivered full size IgGs are often hampered by their insufficient penetration into solid tumors because extravasation from the circulation and penetration into solid tumors against a hydrostatic pressure gradient is a size-dependent process and has been found to be slow for a molecule with a size of 150 kDa. 44, 45 Another beneficial advantage may be that high local antibody concentrations should be maintained as long as tumor cells are present as host/substrate for the virus and therefore will allow the full exertion of the therapeutic effect of the antibody.
To examine the virus-mediated antibody expression in an intact tumor, an initial in vivo experiment, injecting the antibody-encoding NDV directly into fibrosarcoma xenografts, was performed. Three days after the infection and after subsequent immunohistochemical analysis, a specific pattern of antibody staining against ED-B was only visible in cryosections of MTH146-infected but not control in virus-infected tumors. This result demonstrates the antibody expression by NDV and the antigen recognition in tumor tissue in vivo. Future work will address the previously discussed questions like therapeutic efficacy, amplification of antibody expression by viral replication, target saturation and tumor penetration.
The oncolytic virus mediated expression of antibodies by tumor cells is an example how the therapeutic potency of the oncolytic virus NDV can be enhanced and how the advantages of this system can be used to improve other existing approaches such as antibody therapy. Given the tumor-selective replication and transgene expression of the oncolytic virus, it will now be possible to target antibodies or other therapeutic proteins to the tumor, which are not tumor-selective by themselves and would be too toxic to be used systemically for example, apoptosis-inducing antibodies or cytokines (tumor necrosis factor, interleukin-12 and so on). Also therapeutic approaches employing intrabodies, that is, antibodies against intracellular targets, can now be envisaged since this approach overcomes the so far unsolved delivery issue. 46 In this study we show that a full IgG antibody can be expressed from transgenes specifically in tumor cells, what had not been shown before to our knowledge. Although tumor cells generally do not secrete antibodies it is possible to generate fully functional antibody from all tumor cell lines tested. The order of the transgenes for the heavy and the light chain within the virus genome therefore appears favorable for the formation of functional full IgGs after infection of host cells. After having shown this proof-of-principle for the expression of a full IgG antibody by an oncolytic paramyxovirus, it will now be possible to engineer various suitable antibodies and antibody-fusion proteins into the genome of oncolytic NDV and other oncolytic paramyxoviruses to enhance their potency for the treatment of tumors. 
Materials and methods
Cloning of the full-length genome
The cloning of the full-length genome MTH68 was performed analogously to Römer-Oberdörfer et al.
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Briefly, the oncolytic NDV strain MTH68 was grown in embryonated chicken eggs, the allantoic fluid was harvested and virus was concentrated by ultracentrifugation (2 h, 20 000 g). The pellet was resuspended with phosphate-buffered saline (PBS) and viral RNA was isolated using the QIAamp viral RNA kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. From the resulting RNA 5 mg was used for each RT (Superscript kit; Promega, Heidelberg, Germany) with gene-specific primers. Subsequently PCR was carried out with PFU proofreading DNA polymerase resulting in the genomic fragments A through E of MTH68. cDNAs were cloned by TA-cloning into the shuttle plasmids pbluescript or pcDNA3 (Clontech, Heidelberg, Germany). Primers were designed based on the published sequence of the strain LaSota and own sequencing data. Primer sequences are available on request. In a multistep (15 steps) cloning procedure the six fragments (A-E) were assembled with the vector plasmid pX8dT 34 to obtain a full-genome cDNA plasmid that was termed pflMTH68. For the generation of the correct 5 0 end of the viral genome, a SmaI site was used. For the 3 0 end of the cDNA digestion with Esp3 plus fill-in was used to generate the correct end of the genomic sequence.
Helper plasmids, which express the mRNA of the proteins N, P and L of the RNP were cloned using the pCite2a vector (Novagen, Bad Soden, Germany). Briefly, from virus RNA, RT-PCR was performed with primers derived from the MTH68 genome sequence containing restriction sites for NcoI and XbaI. PCR fragments were then cloned into the NcoI and XbaI sites of the plasmid pCITE2a, resulting in the plasmids pCITE N MTH68, pCITE P MTH68 and pCITE L MTH68.
Cloning of additional transcriptional cassettes
The two DNA oligonucleotides Sfi fw (5 0 -aggccttaat taaccgacaacttaagaaaaaatacgggtagaacggcctgag-3 0 ) and Sfi back (5 0 -aggccgttctacccgtattttttcttaagttgtcggttaattaaggcc tctc-3 0 ) were annealed and subsequently ligated into the naturally occurring unique SfiI site of pflMTH68. The resulting plasmid pflMTH68 Pac was cut with PacI and another dsDNA oligonucleotide, consisting of the annealed single-stranded oligomers Asc fw (5 0 -cgg gcgcgccccgacaacttaagaaaaaatacgggtagaacagcagtcttcagtctt aat-3 0 ) and Asc back (5 0 -taagactgaagactgctgttctacccg tattttttcttaagttgtcggggcgcgcccgat-3 0 ), was inserted into the PacI-restriction site thereby destroying one of the flanking PacI-recognition sites and inserting a unique AscI site. The resulting plasmid was designated pflMTH68 Asc Pac. This plasmid has two additional transcriptional cassettes inserted between the genes for the viral F and HN genes.
The gene for EGFP was amplified from the plasmid pEGFP-IRESneo (Clontech) with the primers GFPPacfw 5 0 -cgcttaattaaccaccatggtgagcaagggcgaggagctg-3 0 and GFPPacback 5 0 -cggttaattaacttacttgtacagctcgtccatgccg-3 0 containing flanking PacI recognition sites. The PCR fragment was cloned into the plasmid pcDNA3 resulting in plasmid pcDNA3 EGFP Pac. From pcDNA3 EGFP Pac, the EGFP gene was excised with PacI and cloned into the PacI site of pflMTH68 Pac yielding pflMTH87.
The gene for the E. coli b-glucuronidase was amplified from E. coli genomic DNA with the primers GlucPacfw 5 0 -ccttaattaaccaccatgttacgtcctgtagaaaccc-3 0 and GlucPacback cccttaattaactcattgtttgcctccctgctgc and cloned analogously to EGFP into the PacI site of pflMTH68 yielding pflMTH115.
The heavy and light chains of a full-length IgG recombinant function-blocking antibody against the ED-B type III (ED-B) of fibronectin (MOR03257) were cloned into the two additional unique restriction sites AscI and PacI, respectively. From expression plasmids the DNA was amplified with the following primers containing appropriate restriction sites: heavyPacfw:
0 (restriction recognition sites in bold). The PCR fragments were cloned by TA cloning into the expression plasmid pcDNA3, yielding pcDNA3 light and pcDNA3 heavy. The correct orientation for use in transfection experiments was verified by restriction enzyme digest. The murine IgG-l light chain for the anti-ED-B antibody was cloned from pcDNA3 light into the AscI site of pflMTH68AscPac yielding pflMTH68lightPac. The murine IgG heavy chain for the anti-ED-B antibody was cloned from pcDNA3heavy into the PacI site of pflMTH68lightPac yielding pflMTH146. The length of the inserts together with the adapter sequences was adjusted to a base number which was a multiple of six in order to follow the rule of six for the length of the complete genome of the recombinant virus.
Rescue of recombinant virus
Recombinant virus was rescued as described previously. 17 Briefly BHK-T7 cells in six-well plates were co-transfected using Lipofectamine with 0.2 mg pCITE N, 0.2 mg pCITE P, 1.0 mg pCITE L and 5 mg of the genomic plasmid (DNA:Lipofectamine ¼ 2:3). Two days after transfection recombinant virus was harvested from the supernatant of the cells. According to the full-length genomic plasmids that were used in the transfection the recombinant viruses were termed MTH87 (EGFP), MTH115 (b-glucuronidase) and MTH146 (ED-B antibody).
Virus titration
Virus titers were determined by plaque-formation assay using HT1080 cells in a 24-well format. After attachment (1 h) of virus to the cells, the inoculum was removed and replaced with 1% agarose-containing medium. Plaques were counted 24 h after the infection.
Infection
If not stated otherwise, cells were washed once with PBS for 5 min prior to infection. Virus was diluted appropriate in serum-free media. Cells were incubated with virus for 1 h on a shaker in the 37 1C incubator. The volume of the inoculum was 100 ml for 96 wells, 300 ml for 24 wells, 1.0 ml for 6 wells. After the infection the inoculum was replaced by serum-containing fresh medium.
For the live-cell microscopy HT29 cells were seeded at 10 6 cells per 6 cm dish. For the infection a calculated number of 30 PFU were used. A GFP-expressing cell was searched (15 h after the infection) by fluorescence microscopy within the dish and recording of the photographs was started (for 48 h every 5 min).
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The images were taken using a Zeiss microscope and Axiovision software.
For the in vivo infection nude mice bearing subcutaneous HT1080 tumors (mean tumor area 110 mm 2 ) were infected intratumorally with 9 Â 10 6 PFU in 100 ml. Virus was grown in allantoic fluid of chicken eggs and diluted in PBS.
Cell viability assay
Cell viability was measured based on the presence of ATP in living cells. The CellTiterGlo assay from Promega was used according to the manufacturers instructions. In the 96-well format, the virus was not aspirated after the infection. Instead 200 ml of fresh medium were added on top of the 100 ml inoculum.
Co-culture of cells
One-time 10 6 cells per well of HaCaT and HT29 cells were plated in multiple six-well plates. Adherent HaCaT cells were stained with 5 mM CellTrackerOrange (Molecular Probes, Leiden, the Netherlands) for 45 min at 37 1C. After staining the cells were incubated for 30 min with fresh medium in the incubator and subsequently the cells were once washed with PBS and then incubated with fresh medium over night. HaCaT cells and HT29 tumor cells were trypsinized 24 h after staining. Cells were mixed at ratios 1:9, 1:1 and 9:1, centrifuged (5 min 1000 g) and resuspended in Dulbecco's modified Eagle's medium Ham's F12 medium. Cells were plated at the same density as before trypsinization (1:1) in six-well dishes. Infection was performed as described above.
Transfection
A total of 10 5 CHO cells per six-well dish were plated four times 1 day prior to transfection with expression plasmids. Cells were transfected with FuGENE 6 (Roche, Mannheim, Germany). Two days after transfection the cell supernatant was harvested and centrifuged for 1 min at 13 000 g The supernatant was frozen at À20 1C until subsequent analysis in ELISA.
ELISA
LumiNunc plates (Nunc) were coated with recombinant antigen ED-B 3 mg ml À1 for 1 h at 37 1C. Plates were blocked with PBS, 1% bovine serum albumin, 0.5% Tween 20 for 1 h at 37 1C. As a standard, purified recombinant anti-EDB antibody (expressed from CHO cells) was serially diluted from 1000 to 1.5 ng ml À1 . A total of 10 ml of sample was loaded to 90 ml buffer in each well and incubated for 1 h at 37 1C. After binding the solution was aspirated. In order to inactivate virus from the supernatant of infected cells, all wells were incubated with 4% formaldehyde for 20 min and subsequently washed with buffer. As secondary antibody for detection, a peroxidase-conjugated goat anti-mouse IgG F(ab)2-fragment (no. 610-1304; Rockland, Gilbertsville, PA, USA) was used at a dilution of 1:7500. A total of 100 ml of antibody was incubated in each well for 1 h at 37 1C. Peroxidase was detected with Luminol (Roche) (5 min) and light emission detected using a Luminometer (Victor, Perkin Elmer, Weiterstadt, Germany).
Immunofluorescence
Two days after the infection the cells were fixed with 4% formaldehyde. The cells were washed and bound antibody was visualized by staining with a Cy3-coupled secondary antibody directed against mouse IgG (Jackson Immuno Research, West Grove, PA, USA; 115-165-146). As a positive control, mock-infected cells were incubated prior to fixation for 1 h with 5 mg ml À1 (final concentration in medium) recombinant anti-ED-B IgG MOR03257.
Immunohistochemistry
Cryopreserved tissue sections (10 mm) of the SK-MEL melanoma or HT1080 fibrosarcoma grown as xenografts subcutaneously in mice were fixed in cold acetone for 10 min, washed in PBS and stained with antibody. As control served a purified a-ED-B IgG antibody MOR03257 (concentration 5 mg ml À1 for staining) that was expressed from stably transfected 293 cells. The negative control was incubated with buffer only and no primary antibody. The supernatants of 293 cells or HT29 tumor cells that had been infected with recombinant viruses were used for staining as undiluted supernatants. Prior to staining, virus was inactivated by treatment with UV light. Control-infected cells were infected with a recombinant virus (MTH115) that did not produce an antibody as a transgene. The bound antibody was visualized by detection with protein-A peroxidase (Sigma, Deisenhofen, Germany) and staining with diaminobenzidine (Dako, Hamburg, Germany) or AEC (Dako) as a substrate. The sections were counterstained with hematoxylin QS (Dako). Photodocumentation was performed with a Zeiss Axiophot imaging system.
